No evidence for TSLP pathway activity in human breast cancer - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue OncoImmunology Année : 2016

No evidence for TSLP pathway activity in human breast cancer

Résumé

Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine that primes dendritic cells for Th2 induction. It has been implicated in different types of allergic diseases. Recent work suggested that TSLP could play an important role in the tumor microenvironment and influence tumor progression, in particular in breast cancer. In this study we systematically assessed the production of TSLP at the mRNA and protein levels in several human breast cancer cell lines, large-scale public transcriptomics data sets, and primary human breast tumors. We found that TSLP production was marginal, and concerned less than 10% of the tumors, with very low mRNA and protein levels. In most cases TSLP was undetectable and found to be expressed at lower levels in breast cancer as compared to normal breast tissue. Last, we could not detect any functional TSLP receptor (TSLPR) expression neither on hematopoietic cells nor on stromal cells within the primary tumor microenvironment. We conclude that TSLP-TSLPR pathway activity is not significantly detected within human breast cancer. Taken together, these observations do not support TSLP targeting in breast cancer.

Dates et versions

hal-01607902 , version 1 (03-10-2017)

Identifiants

Citer

Cristina Ghirelli, Benjamin Sadacca, Fabien Reyal, Raphael Zollinger, Paula Michea, et al.. No evidence for TSLP pathway activity in human breast cancer. OncoImmunology, 2016, 5 (8), pp.1-32. ⟨10.1080/2162402X.2016.1178438⟩. ⟨hal-01607902⟩
98 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More